论文部分内容阅读
目的:探究肠易激综合征患者采用思密达与多虑平联合治疗的临床效果。方法:选取我院2014年7月-2015年8月收治的92例肠易激综合征患者,按照不同的治疗方式分成观察组和对照组,各46例。观察组通过思密达联合多虑平治疗,对照组给予单存思密达治疗,对比两组临床疗效。结果:观察组的治疗总有效率95.65%,对照组的治疗总有效率73.91%,组间比较,差异显著,P<0.05。结论:肠易激综合征经思密达、多虑平联合治疗,治疗效果较佳,且能够有效的改善患者的临床症状和精神状态,值得临床深入推广。
Objective: To investigate the clinical effect of combined treatment of Smecta and doxepin in patients with irritable bowel syndrome. Methods: A total of 92 patients with IBS admitted to our hospital from July 2014 to August 2015 were selected and divided into observation group and control group according to different treatment methods, with 46 cases in each group. Observation group through metamizumab combined with doxepin treatment, the control group was given a single Smectite treatment, the clinical efficacy of the two groups were compared. Results: The total effective rate of the observation group was 95.65%, while that of the control group was 73.91%. There was significant difference between the two groups (P <0.05). Conclusion: The treatment of irritable bowel syndrome combined with Smecta and Doxepin has good curative effect and can effectively improve the patients’ clinical symptoms and mental status, which deserves further clinical promotion.